June 12, 2020 04:46 PM EDT
R&D

UCB flash­es the da­ta be­hind its pos­i­tive pso­ri­a­sis read­outs. Can it com­pete in a crowd­ed field?

Jason Mast

Editor

Eight months af­ter UCB an­nounced that a lit­tle-watched drug can­di­date out­per­formed J&J’s block­buster Ste­lara, the Bel­gian phar­ma is out with full da­ta that one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times